Nature Medicine, Published online: 18 April 2025; doi:10.1038/s41591-025-03645-3 The authors found, after analyzing 10,960 individuals from 9 multiancestry biobanks across 6 countries, that genetic factors previously associated with BMI have limited impact on GLP-1 receptor agonist-induced weight loss.
After the tireless, incredible work by the scientists involved, the marketing team will barely have to lift a finger to come up with something catchier than orforglipron, as the company’s potentially game-changing drug has been dubbed. Eli Lilly announced trial results Thursday that suggested the experimental pill for diabetes and weight loss is just as … Read more
The News Eli Lilly’s share price soared after it said a daily weight-loss pill showed similar results to injectable drugs Ozempic and Mounjaro. Orforglipron helped patients lose an average 7.9% of their body weight in 40 weeks in clinical trials, compared with the 1.6% weight lost by those taking a placebo. The drug was less … Read more
The first daily weight-loss pill is expected to be available in the UK as soon as next year after a trial found it to be effective in treating obesity and diabetes. The drug, developed by Eli Lilly and called orforglipron, targets the same GLP-1 receptors as injectable weight loss drugs such as Ozempic, Wegovy and Mounjaro. … Read more
We recently published a list of 10 Firms End Stronger, Buck Muted Broader Market Trading. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading week mixed, with two of the major … Read more
INDIANAPOLIS, April 17, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and…
A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster drugs like Ozempic-and the risk of depression and suicidal ideation (SI).
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP receptor agonists (that include semaglutide and tirzepatide).
What to Know About Eli Lilly’s Daily Pill for Weight Loss The New York TimesView Full Coverage on Google News
